CC-8490

CC-8490 is an investigational **benzopyran small molecule** developed for oncology, including a Phase 1 study sponsored by the National Cancer Institute in recurrent or refractory high-grade glioma. Available public cancer-dictionary sources describe CC-8490 as a **selective estrogen receptor modulator** with potential antineoplastic activity that inhibits proliferation of estrogen-sensitive tumor cells; in glioblastoma models, it has also been reported to inhibit growth and induce apoptosis through a mechanism that may be at least partly independent of classical estrogen receptor signaling. In the specific NCI high-grade glioma context, it was studied as an **oral antineoplastic agent** in a dose-escalation trial evaluating safety, pharmacokinetics, and maximum tolerated dose.